RxDoctor Payments DataLook up a doctor →

Joseph Stauber, MD

Rheumatology · Saint Louis, MONPI 1548609779

Payments from drug & device makers

$62,334in general payments, 2019–2025

Across 1,682 payments — averaging $37.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$22K
  • Amgen$12K
  • AbbVie$7K
  • Johnson & Johnson$5K
  • UCB, Inc.$2K
  • Pfizer$2K
  • plus $11K from 45 others
$1,281in research payments, 2019–2025

Across 13 payments — averaging $98.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sun Pharmaceutical Industries Inc.15$21,888
Amgen(2 entities)279$12,181
AbbVie232$7,008
Johnson & Johnson(2 entities)220$5,322
UCB, Inc.152$2,493
Pfizer158$2,160
Novartis128$2,082
AstraZeneca(2 entities)67$1,369
Lilly USA, LLC77$1,330
GSK57$904
E.r. Squibb & Sons, L.L.C.46$702
Boehringer Ingelheim27$487
Bristol Myers Squibb38$466
Sanofi19$364
Janssen Scientific Affairs, LLC3$364
Organon17$349
Sobi, Inc12$314
Radius Health, Inc.14$274
Aurinia Pharma U.S., Inc.14$264
Teva Pharmaceuticals USA, Inc.6$228
Mallinckrodt Hospital Products Inc.9$197
Genentech USA, Inc.12$191
Fresenius Kabi USA, LLC7$121
Grifols USA, LLC5$110
Medexus Pharma, Inc.7$99
Kiniksa Pharmaceuticals International, PLC4$93
Sandoz6$87
Sanofi-aventis U.S. LLC4$78
Tersera Therapeutics LLC4$77
Hospira, Inc.4$76
Pacira Therapeutics, Inc.5$71
Octapharma USA, Inc.3$63
Kiniksa Pharmaceuticals, Ltd.3$57
Merck4$55
Antares Pharma, Inc.2$48
Mylan Institutional Inc.2$39
Ultragenyx Pharmaceutical Inc.2$37
Kyowa Kirin, Inc.2$33
Mallinckrodt Enterprises LLC2$32
Hikma Pharmaceuticals USA2$31
Orthogenrx Inc.1$23
Pharmacosmos Therapeutics Inc.1$23
Zyla Life Sciences, Inc.2$23
Sebela Pharmaceuticals Inc.1$18
Celltrion USA Inc.1$17
Actelion Pharmaceuticals US, Inc.1$17
ANI Pharmaceuticals, Inc.1$16
Tonix Medicines, Inc.1$15
Invivyd Inc1$14
Cumberland Pharmaceuticals, Inc.1$13
Fidia Pharma USA Inc.1$11

How this compares

$62,334 in reported general payments places this provider in the 85th percentile of 134 rheumatology providers in Missouri.

See all rheumatology providers in Missouri →

Medicare billing

Part B allowed, 2024
$3,626,942
Medicare patients
526
Services billed
207,679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Saint Louis

See the full list for Missouri →

Where these figures come from

Is this you, or does something look wrong? →